ATE429905T1 - PHARMACEUTICAL COMPOSITION CONTAINING OXCARBAZEPINE WITH CONTROLLED RELEASE - Google Patents
PHARMACEUTICAL COMPOSITION CONTAINING OXCARBAZEPINE WITH CONTROLLED RELEASEInfo
- Publication number
- ATE429905T1 ATE429905T1 AT03730048T AT03730048T ATE429905T1 AT E429905 T1 ATE429905 T1 AT E429905T1 AT 03730048 T AT03730048 T AT 03730048T AT 03730048 T AT03730048 T AT 03730048T AT E429905 T1 ATE429905 T1 AT E429905T1
- Authority
- AT
- Austria
- Prior art keywords
- pharmaceutical composition
- composition containing
- controlled release
- containing oxcarbazepine
- oxcarbazepine
- Prior art date
Links
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000013270 controlled release Methods 0.000 title 1
- 229960001816 oxcarbazepine Drugs 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the pharmaceutical compositions, especially for oral administration, containing therapeutically efficient quantity of oxcarbazepin with prolonged release of the active ingredient in vitro.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10224170A DE10224170A1 (en) | 2002-05-31 | 2002-05-31 | Retarded release pharmaceutical composition, obtained without use of organic solvents or water by densifying mixture of active agent and retarding polymer in heated rollers |
| DE10224177 | 2002-05-31 | ||
| DE10250566A DE10250566A1 (en) | 2002-05-31 | 2002-10-30 | Pharmaceutical composition containing oxcarbazepine, having suitable release profile for once-daily administration in treatment of epilepsy, pain or alcohol withdrawal symptoms |
| PCT/EP2003/005116 WO2003101430A1 (en) | 2002-05-31 | 2003-05-15 | Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE429905T1 true ATE429905T1 (en) | 2009-05-15 |
Family
ID=40600478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03730048T ATE429905T1 (en) | 2002-05-31 | 2003-05-15 | PHARMACEUTICAL COMPOSITION CONTAINING OXCARBAZEPINE WITH CONTROLLED RELEASE |
Country Status (4)
| Country | Link |
|---|---|
| KR (1) | KR20050010843A (en) |
| AT (1) | ATE429905T1 (en) |
| DE (1) | DE50311479D1 (en) |
| MD (1) | MD20040296A (en) |
-
2003
- 2003-05-15 DE DE50311479T patent/DE50311479D1/en not_active Expired - Lifetime
- 2003-05-15 AT AT03730048T patent/ATE429905T1/en not_active IP Right Cessation
- 2003-05-15 MD MDA20040296A patent/MD20040296A/en not_active Application Discontinuation
- 2003-05-15 KR KR10-2004-7019282A patent/KR20050010843A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MD20040296A (en) | 2005-05-31 |
| KR20050010843A (en) | 2005-01-28 |
| DE50311479D1 (en) | 2009-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG66093B1 (en) | Controlled release compositions comprising nimesulide | |
| EE200300033A (en) | Cyclopentanoindoles, their use in the preparation of a medicament, and the pharmaceutical composition containing them | |
| NO330947B1 (en) | The use of oxcarbazepine-containing pharmaceutical compositions in the fasted state | |
| ATE302616T1 (en) | MEDICINAL COMPOSITIONS FOR ORAL APPLICATION WITH CONTROLLED RELEASE OF ACTIVE INGREDIENTS | |
| PL370292A1 (en) | Formulations for oral administration of active compounds | |
| CY1111470T1 (en) | NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLYVERSERIN POLYMORPH A | |
| MXPA03007857A (en) | Compounds and compositions for delivering active agents. | |
| EA200901393A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING GESTAGENES AND / OR ESTROGENS AND 5 METHYL- (6S) -TETRAHYDROPHOLATE | |
| BR0311327A (en) | Oxcarbazepine-containing pharmaceutical composition with sustained release of an active ingredient | |
| ATE252377T1 (en) | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING TILIDINE MESYLATE AS THE ACTIVE INGREDIENT | |
| DE69923336D1 (en) | ORANGE BUPRENORPHINIC MEDICINAL PRODUCTS TO BE APPLIED | |
| AP2003002763A0 (en) | Controlled release formulations for oral administration | |
| AU2002214389A1 (en) | Pharmaceutical composition containing honey for the treatment of wounds | |
| DE60205905D1 (en) | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION WITH IMPROVED BIOAVAILABILITY | |
| DE602004016963D1 (en) | Therapeutisches system mit amoxicillin und clavulansäure | |
| NO20064808L (en) | Oral matrix formulations with licarbazepine | |
| TW200503785A (en) | Dosage form containing (S)-pantoprazole as active ingredient | |
| EA200601015A1 (en) | ORAL COMPOSITIONS OF DEOXYPEGANINE AND THEIR APPLICATION | |
| ATE460934T1 (en) | PHARMACEUTICAL PREPARATIONS OF CIPROFLOXACIN | |
| ATE357220T1 (en) | MODIFIED RELEASE PHARMACEUTICAL COMPOSITION | |
| ATE429905T1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING OXCARBAZEPINE WITH CONTROLLED RELEASE | |
| SE0203817D0 (en) | New composition | |
| WO2001095890A3 (en) | Oral pharmaceutical compositions containing terbinafine | |
| TNSN06299A1 (en) | Oral matrix formulations comprising licarbazepine | |
| MY145885A (en) | Controlled release formulations for oral administration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REN | Ceased due to non-payment of the annual fee |